Phyllis K. Bellin

American Roadside Burgers produces and supplies hamburgers and cheeseburgers. It offers turkey burgers, hot dogs, fries and traditional milkshakes. The company was founded by John J. Tunney in 2002 and is headquartered in Huntington, NY.

Merz Pharmaceuticals GmbH discovers and develops drugs for the treatment of neurological and psychiatric diseases. Its dermatology products focus on the treatment of scars, acne, hair loss and fungal diseases. In the area of metabolic disturbances, it offers therapies for liver disease and lipid metabolism disorders. The company also offers various OTC products, including cold remedies, skin care products and vitamin supplements under the brand names tetesept and Merz Special. The company is headquartered in Frankfurt am Main, Germany.

New York State Bar Association is a non-profit organization, which provides legal services and offers a membership program for lawyers. It also publishes an array of books, bar journals, law digest, and State Bar news. The company was founded in 1876 and is headquartered in Alban, NY.

The American Glaucoma Society supports glaucoma specialists and scientists through the advancement of education and research.

First Wave Technologies, Inc. is a medical device company, which develops products for acute care and long-term care markets. The firm focuses on healthcare innovation products. It engages in improving the ease and accuracy of pharmaceutical delivery and providing healthcare experience for both patients and caregivers. The company was founded by Mark S. Dowhy, Bradley P. Fuhrman and Keith Allen Blakely in 2003 and is headquartered in Batavia, NY.

Regenovation, Inc. develops ways to regenerate human tissue. The company is headquartered in New York, NY.

Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY.

Legacy Education Alliance International Ltd. provides financial and personal development training program services. The company was founded on October 26, 2001 and is headquartered in Richmond, the United Kingdom.

BELKIN Vision Ltd. provides glaucoma laser treatment. The company was founded by Michael Belkin in 2013 and is headquartered in Tel Aviv, Israel.

LB Pharmaceuticals, Inc. provides pharmaceutical services. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York, NY.

Neuraptive Therapeutics, Inc. engages in developing therapeutic technology for the acute surgical repair of injured peripheral nerves. Its products include AxoFuse, AxoTrim, and AxoBond. The company was founded by David Jackson in 2016 and is headquartered in Lafayette, Co.

InFocus Capital Partners (InFocus Capital Partners) is a venture capital firm founded in 2016 by Rob Rothman and Ron Weiss. The firm is headquartered in Jericho, New York.

Sustained Nano Systems LLC is a company that develops products for post-cataract surgery treatment. The company is based in Westhampton Beach, NY and was founded by Barry M. Libin, who has been the CEO since incorporation. The company's products include dex-sa, which delivers dexamethasone to the subconjunctival space to treat postoperative inflammation and pain, and lat-la, a single extraocular injectable administration of a six-month release prostaglandin analog for glaucoma treatment. The company also develops SNS ret-la, which prevents blood vessel growth for over a year in a standard rabbit model of corneal angiogenesis.

Ocugenix Corp. operates as a therapeutics company focusing on he development of of cancer immunotherapy drug for eye diseases. The company is headquartered in Pittsburgh, PA.

Secarna Pharmaceuticals GmbH & Co. is a leading German European pharmaceutical company that specializes in next-generation antisense drug discovery and development. The private company focuses on addressing high unmet medical needs in immuno-oncology, immunology, viral, neurodegenerative, and cardiometabolic diseases. Secarna's mission is to develop highly specific, safe, and efficacious antisense therapies using its proprietary LNAplus antisense oligonucleotide discovery platform. The company has over 20 discovery and development programs, including both proprietary pipeline projects and partnered programs, and focuses on targets in indications where antisense-based approaches have clear potential benefits over other therapeutic modalities.